Overview

Study of the Sars-Cov2 Neuroinvasiveness - COVID19

Status:
Recruiting

Trial end date:
2023-01-01

Target enrollment:
0

Participant gender:
All

Summary

Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Fondation Ophtalmologique Adolphe de Rothschild

Criteria

Inclusion Criteria:

- COVID-19 patients requiring an external ventricular drain, a decompressive craniectomy
or an intracranial hematoma surgery

Exclusion Criteria:

- Pregnant or lactating women